1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • July 2014
  • -
  • GlobalData
  • -
  • 90 pages

Summary

Table of Contents

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Evolocumab is a member of the emerging class of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, fully human monoclonal antibodies (mAbs) that prevent the degradation of LDL-C receptors in the liver. This novel mechanism of action increases the body’s ability to filter LDL-C from the circulation. Evolocumab is one of several PCSK9 inhibitors navigating critical Phase III clinical trials in a race to achieve regulatory approval.

Scope

- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Lipid Regulators Market Growth, Trends & Forecast (2017 - 2022)

Global Lipid Regulators Market Growth, Trends & Forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The Global Market for Lipid Regulators accounted for $XX billion in 2014 and the market size is estimated to grow up to $XX billion by 2020 with CAGR at XX%. Lipid regulators or lipid-regulating drugs ...

Global Dyslipidemia Drugs Market 2017-2021

Global Dyslipidemia Drugs Market 2017-2021

  • $ 3500
  • Industry report
  • March 2017
  • by Infiniti Research Limited

About Dyslipidemia Drugs Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia ...

Atorvastatin / Ezetimibe Sales, Price Analysis, & Sales Forecast - 2017

Atorvastatin / Ezetimibe Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Atorvastatin / Ezetimibe Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Atorvastatin / Ezetimibe worldwide and by countries in North ...


Download Unlimited Documents from Trusted Public Sources

Global Lipid Modifying Drug and Therapy Market - Forecast

  • March 2017
    3 pages
  • Lipid Modifying...  

    Therapy  

    Statins  

  • World  

    United States  

View report >

Global Cardiovascular Disease Statistics and Lipid Modifying Drug Market - Forecast

  • January 2017
    3 pages
  • Cardiovascular ...  

    Lipid Modifying...  

    Therapy  

  • World  

    United States  

    Europe  

View report >

Lipid Modifying Drug Market in the US

  • January 2017
    48 pages
  • Lipid Modifying...  

    Therapy  

    Opioid  

  • United States  

View report >

Related Market Segments :

Lipid Modifying Drug

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.